3-MeO-PCP (3-Methoxyphencyclidine)
Potent arylcyclohexylamine dissociative anesthetic, more potent and stimulating than PCP or ketamine. NMDA channel blocker (high potency) + SERT inhibitor + sigma-1 agonist. Produces dissociation, euphoria, and mania/psychosis at high doses. Longer duration than ketamine with more pronounced manic/psychotomimetic effects. CYP2B6 and CYP3A4 substrate. Sold as a "research chemical" with significant harm potential — narrow dose-response curve; small dose increases produce disproportionately severe effects. Mania and psychosis are first-order risks beyond dissociative effects alone.
Projected serum levels — 5 mg, as needed (shown daily)
Maintenance schedule: 5 mg as needed (shown daily) (oral).
Modeled steady state after ~1 days: peak ≈ 3.7 mg, trough ≈ 0.62 mg body load. Population-based estimate over 15 days for a 5 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Dissociative
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 8 h
- Common dose
- 5 mg
- Suggested maximum
- 15 mg/day
- Reference dose range
- 2–15 mg (single dose)
- Suggested cadence
- as needed (shown daily)
Documented interactions
-
danger
1P-LSD (1-Propionyl-LSD) + 3-MeO-PCP (3-Methoxyphencyclidine)
1P-LSD (1-Propionyl-LSD) and 3-MeO-PCP (3-Methoxyphencyclidine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
25I-NBOMe + 3-MeO-PCP (3-Methoxyphencyclidine)
25I-NBOMe and 3-MeO-PCP (3-Methoxyphencyclidine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
2C-I (2,5-Dimethoxy-4-iodophenethylamine) + 3-MeO-PCP (3-Methoxyphencyclidine)
2C-I (2,5-Dimethoxy-4-iodophenethylamine) and 3-MeO-PCP (3-Methoxyphencyclidine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered…
-
danger
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + 3-MeO-PCP (3-Methoxyphencyclidine)
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and 3-MeO-PCP (3-Methoxyphencyclidine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered…
-
danger
4-AcO-DMT (Psilacetin) + 3-MeO-PCP (3-Methoxyphencyclidine)
3-MeO-PCP (3-Methoxyphencyclidine) and 4-AcO-DMT (Psilacetin) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) + 3-MeO-PCP (3-Methoxyphencyclidine)
3-MeO-PCP (3-Methoxyphencyclidine) and 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered…
Serum checks 175 modeled interaction pairings for 3-meo-pcp (3-methoxyphencyclidine) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
From PCP to MXE — a comprehensive review of the non-medical use of dissociative drugs
Comprehensive review of arylcyclohexylamine dissociative pharmacology including 3-MeO-PCP, characterizing its higher potency relative to PCP, SERT inhibitory activity, and the elevated mania/psychosis risk compared to…
-
3-MeO-PCP — PsychonautWiki
Community knowledge base documenting 3-MeO-PCP dose ranges (threshold 1-3mg, light 3-5mg, common 5-10mg, strong 10-15mg, heavy 15mg+), duration (4-8h oral, 3-5h insufflated), onset, subjective effects, and…
2 published studies referenced in the app, each with a plain-language summary.